Proton and Neutron Beam Therapies
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.70 alerts
Get alerted when Policy CP.MP.70 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and coverage criteria for proton beam therapy (PBT) and neutron beam therapy (NBT) for members of health plans affiliated with Centene Corporation (Arizona Complete Health). Applies to clinician requests for PBT/NBT authorization and coverage decisions.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Medically Necessary PBT Indications
PBT is medically necessary when ANY of the following specific indications are met:
These indications are drawn directly from the policy enumerated criteria (I.A through I.W).
Medically Necessary NBT Indications
NBT is medically necessary in salivary gland tumors when any of the following are met:
NBT has most commonly been studied in salivary gland tumors; use is limited and should be considered only in these circumstances.
Not Medically Necessary
Not medically necessary stance:
Requests for indications not listed should be considered non-covered unless new evidence or criteria revisions are provided.
Criteria additions and revisions (summary)
Policy includes multiple specific clinical indications and iterative annual updates; the document references numerous criteria (I.A through at least I.W) added or revised over time.
Revision history documents successive annual updates (policy developed 03/14 with multiple revisions through 11/24) that broadened and clarified the listed criteria.
NBT — NCCN stance for salivary gland tumors
Clinical stance on Neutron Beam Therapy (NBT) for salivary gland tumors according to NCCN.
This guidance provides clinical context when evaluating NBT requests for salivary gland tumors.
All indications for proton beam therapy (PBT) and neutron beam therapy (NBT) that are not explicitly listed as medically necessary in this policy are considered not medically necessary. This policy requires that requests for PBT or NBT meet one of the specified covered indications; treatments for unlisted indications do not meet the plan’s medical necessity criteria and are subject to denial.
Although NBT has been studied historically for salivary gland tumors, the National Comprehensive Cancer Network (NCCN) no longer recommends neutron beam therapy as a routine solution for salivary gland cancers because of diminishing demand, high rates of long-term toxicity, concerns about the methodological robustness of randomized trial data, and closure of most U.S. centers; NCCN does acknowledge possible value for select patients in limited circumstances.
Because the available evidence does not demonstrate that PBT or NBT is superior to other available treatments for indications not listed in this document, those other uses are considered not medically necessary. Coverage decisions require demonstration that the requested treatment meets one of the policy’s specified medical necessity criteria.
Procedure and billing codes appear in this policy for informational and claims-processing context only. Inclusion or exclusion of any code does not guarantee coverage; providers must still meet the clinical criteria and follow the member’s benefit document and coding guidance for reimbursement.
Procedure and Billing Codes
| 77423 | High energy neutron radiation treatment delivery, 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s) |
| 77520 | Proton treatment delivery; simple, without compensation |
| 77522 | Proton treatment delivery; simple, with compensation |
| 77523 | Proton treatment delivery; intermediate |
| 77525 | Proton treatment delivery; complex |
| S8030 | Scleral application of tantalum ring(s) for localization of lesions for proton beam therapy |
Prior Authorization, Documentation, and Coverage Requirements
Provider action required: Prior authorization is required for proton beam therapy (PBT) and neutron beam therapy (NBT). Coverage with Evidence Development (CED) may be required for select indications per plan guidance. Providers must document clinical rationale and supporting records demonstrating medical necessity.
- Submit prior authorization request before scheduling; include treatment modality (proton vs photon vs neutron), treatment plan, and number of fractions
- If CED applies, include protocol/study identifier and evidence of enrollment or intention to enroll
- For ocular tumors, submit detailed ocular tumor documentation: tumor size, laterality, location, histology, staging, and prior ocular-specific treatments
- Demonstrate why PBT is being requested instead of photon therapy: comparative dosimetry showing reduced dose to critical structures or other clinical justification
- Include complete medical necessity documentation per the Medical Necessity Guide: history, prior therapies, imaging, tumor board notes (if applicable), and anticipated benefit vs risk
- Coding inclusion does not guarantee coverage; providers should verify and use the most current coding guidance prior to claims submission
Provider Requirements, Prior Authorization, and Documentation
Coverage with Evidence Development (CED) required for select indications
Coverage for certain PBT indications (for example, prostate cancer) is recommended only when the patient is enrolled in an IRB‑approved clinical trial or a multi‑institutional registry that meets Medicare CED requirements.
- Radiation therapy under CED should be covered by the insurer while the patient is enrolled in the IRB‑approved trial or multi‑institutional registry.
Obtain prior authorization and verify benefits
Verify member benefits and obtain any required prior authorization for proton or neutron beam therapy prior to treatment using the referenced CPT/HCPCS codes and plan procedures.
Justify PBT over photon therapy (document organ‑at‑risk/cumulative dose constraints)
Document why photon‑based therapy cannot meet treatment objectives — specifically that normal tissue/organ‑at‑risk constraints or cumulative dose tolerances would be exceeded — when requesting PBT instead of photon therapy.
- Provide dosimetric comparison or clinical justification showing photon therapy would exceed organ‑at‑risk or cumulative tolerance limits (e.g., re‑irradiation scenarios).
Supply clinical justification and supporting records on request
Provide requested clinical information and justification per policy when seeking authorization for proton or neutron beam therapy.
- Supply supporting literature, prior treatment records, and objective measures as available to support medical necessity.
Document ocular tumor localization and fiducial use
For ocular tumor PBT requests, document tumor localization method(s) used (for example: indirect ophthalmoscopy, transillumination, ultrasound, x‑ray, MRI/CT) and note use of radio‑opaque fiducial markers if utilized for treatment planning.
- Include ophthalmologic exam findings, imaging used for target definition, and any fiducial marker placement details.
Follow professional judgment and plan coverage terms; policy guides medical necessity
Use professional medical judgment and adhere to the policy’s terms, conditions, exclusions, and limitations; the clinical policy is a guide to medical necessity but is not a guarantee of payment.
- Providers are responsible for treatment decisions and must follow applicable benefit documents and regulatory requirements.
- Coverage decisions remain subject to plan terms and administrative policies.
Denial risk if indication is not listed as medically necessary
Requests for PBT or NBT for indications not explicitly listed as medically necessary in this policy will be considered not medically necessary and may be denied.
- All other indications for PBT and NBT not listed are considered not medically necessary due to insufficient evidence of superiority.
Clinical Background and Rationale
Proton beam therapy (PBT) is an external beam radiation modality that uses protons to deposit dose with a characteristic depth–dose distribution allowing reduced exit dose and less scatter to surrounding normal tissues compared with photon therapy. This physical property can provide improved sparing of adjacent critical structures and is often beneficial when targets are close to sensitive organs or when minimizing integral dose is important (for example, in pediatric patients or re-irradiation scenarios). Neutron beam therapy (NBT) uses neutrons rather than photons; neutrons are heavier and may cause greater damage in very dense tumors but are more difficult to generate and deliver, limiting availability and routine clinical use.
Definitions
Policy Revision History and References
Annual review updated multiple criteria (I.A–I.H) including adding intraocular melanomas, expanding CNS tumor language, adding pituitary neoplasms, and restructuring criteria sections; references reviewed and updated.
Annual review completed with updates to criteria (I.G expanded to include multiple CNS tumor types and I.H added for pituitary neoplasms); minor background and wording changes; references reviewed and reformatted.
Policy developed and approved; initial policy and background established describing PBT indications and updates to diagnosis code listings.
Selected references informing this policy include peer-reviewed studies, specialty society guidance, and clinical practice guidelines: Eaton BR, Yock T. Cancer J. 2014;20(6):403–408; ASTRO Model Policies: Proton Beam Therapy (2022); multiple NCCN clinical practice guidelines (head and neck; CNS; uveal melanoma; prostate; thymomas; Hodgkin lymphoma; hepatobiliary; sarcoma; NSCLC; pediatric CNS; pediatric Hodgkin lymphoma; mesothelioma); ACR-ARS and ACR-ASTRO practice parameters for proton beam therapy; randomized and nonrandomized clinical studies of proton and neutron modalities in hepatocellular carcinoma, salivary gland cancers, and other tumor types; and technology assessments and local coverage determinations (see full bibliography for complete citations).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.